Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the launch of The GBT Foundation, a 501(c)(3) organization and source of charitable giving that will work to improve the health and well-being of underserve...
The following slide deck was published by Global Blood Therapeutics, Inc. in conjunction with this event. For further details see: Global Blood Therapeutics (GBT) Corporate Presentation
SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 10 th Annual Sickle Cell Disease (SCD) Therapeutics Confere...
New Drug Application for Oxbryta dispersible tablets also accepted for priority review Approximately 17,000 children ages 4 to 11 years have sickle cell disease in the United States SOUTH SAN FRANCISCO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (...
Monday's rise is a good example of a bounce back for blood therapy biotech Global Blood Therapeutics (NASDAQ: GBT) . The stock closed at $27.55 on Friday, hitting a low of $25.61 during the day's trading, which is pretty close to the biotech company's 52-week low of $25.48. On M...
Global Blood Therapeutics is creating a juggernaut blood therapeutics portfolio that could make them the standard bearer in sickle cell disease. Unfortunately, the share price has been sinking along with the rest of the sector, but the recent Q2 earnings beat might change that. Th...
The following slide deck was published by Global Blood Therapeutics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Global Blood Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation
Shares of hematology biotech Global Blood Therapeutics (NASDAQ: GBT) are up 16.5% as of 10:30 a.m. EDT after the company posted upbeat second-quarter 2021 earnings. Sales of its sickle cell disease drug Oxbryta shot up 51% year over year to $47.6 million. In a recent surve...
Earnings remained a substantial mover during Wednesday's midday action. Camping World (NYSE:CWH) and Global Blood Therapeutics (NASDAQ:GBT) both rallied on their respective quarterly reports. Meanwhile, the release of disappointing results sparked declines in shares of Office Depot (NASDAQ:OD...
Gainers: BeyondSpring (NASDAQ:BYSI) +151%, Cerus (NASDAQ:CERS) +21%, Novavax (NASDAQ:NVAX) +18%, Global Blood Therapeutics (NASDAQ:GBT) +17%, SCWorx (NASDAQ:WORX) +14%. Losers: Flora Growth (NASDAQ:FLGC) -25%, Arcturus Therapeutics (NASDA...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...